CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Spyre Therapeutics Inc. - SYRE CFD

    11.7488
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.4324
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Spyre Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* N/A
    Open* N/A
    1-Year Change* N/A
    Day's Range* N/A
    52 wk Range 2.66-25.81
    Average Volume (10 days) 326.13K
    Average Volume (3 months) 2.70M
    Market Cap 784.54M
    P/E Ratio -100.00K
    Shares Outstanding 36.02M
    Revenue 1.05M
    EPS -75.95
    Dividend (Yield %) N/A
    Beta 2.84
    Next Earnings Date Mar 4, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 15, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Apr 2, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Mar 19, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Mar 8, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Feb 26, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Feb 14, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Jan 31, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Jan 19, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Jan 8, 2024 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Dec 27, 2023 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Dec 11, 2023 11.7488 0.0000 0.00% 11.7488 11.7488 11.7488
    Nov 27, 2023 11.7488 1.1400 10.75% 10.6088 12.0588 10.6088
    Nov 24, 2023 11.0288 0.1600 1.47% 10.8688 11.4988 10.6488
    Nov 22, 2023 10.4988 0.8300 8.58% 9.6688 10.7688 9.5988
    Nov 21, 2023 9.6488 -0.7000 -6.76% 10.3488 11.5988 8.5788
    Nov 20, 2023 10.4588 0.7500 7.72% 9.7088 10.9488 9.7088
    Nov 17, 2023 9.9388 -0.0600 -0.60% 9.9988 10.6988 9.5188
    Nov 16, 2023 9.9888 -0.6100 -5.76% 10.5988 11.0288 9.8588
    Nov 15, 2023 10.7588 0.5400 5.28% 10.2188 11.9288 10.2188
    Nov 14, 2023 10.3988 -0.0100 -0.10% 10.4088 10.5488 9.7288

    Spyre Therapeutics Inc. Events

    Time (UTC) Country Event
    Thursday, May 9, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q1 2024 Spyre Therapeutics Inc Earnings Release
    Q1 2024 Spyre Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, May 13, 2024

    Time (UTC)

    16:00

    Country

    US

    Event

    Spyre Therapeutics Inc Annual Shareholders Meeting
    Spyre Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Wednesday, June 5, 2024

    Time (UTC)

    14:00

    Country

    US

    Event

    Aeglea Bio Therapeutics Inc Annual Shareholders Meeting
    Aeglea Bio Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Friday, August 9, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q2 2024 Spyre Therapeutics Inc Earnings Release
    Q2 2024 Spyre Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 2.329 18.739 0 0 3.888
    Revenue 2.329 18.739 0 0 3.888
    Total Operating Expense 87.11 84.388 81.481 80.334 49.351
    Selling/General/Admin. Expenses, Total 28.531 27.319 21.843 15.734 12.632
    Research & Development 58.579 57.069 59.638 64.6 36.719
    Operating Income -84.781 -65.649 -81.481 -80.334 -45.463
    Interest Income (Expense), Net Non-Operating 0.837 0.111 0.593 2.143 1.172
    Other, Net -0.007 -0.122 -0.005 -0.063 -0.057
    Net Income Before Taxes -83.951 -65.66 -80.893 -78.254 -44.348
    Net Income After Taxes -83.815 -65.801 -80.893 -78.254 -44.348
    Net Income Before Extra. Items -83.815 -65.801 -80.893 -78.254 -44.348
    Net Income -83.815 -65.801 -80.893 -78.254 -44.348
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -83.815 -65.801 -80.893 -78.254 -44.348
    Income Available to Common Incl. Extra. Items -83.815 -65.801 -80.893 -78.254 -44.348
    Diluted Net Income -83.815 -65.801 -80.893 -78.254 -44.348
    Diluted Weighted Average Shares 3.37123 2.62978 2.13487 1.27799 0.8329
    Diluted EPS Excluding Extraordinary Items -24.8618 -25.0214 -37.8913 -61.2323 -53.2451
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -24.8618 -25.0214 -37.8913 -61.2323 -53.2451
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.688 0.198 0.168 0.174 0.625
    Total Operating Expense 159.934 19.004 19.33 18.929 23.048
    Selling/General/Admin. Expenses, Total 7.439 5.228 5.079 6.952 7.675
    Research & Development 142.536 13.776 14.251 11.977 15.373
    Operating Income -159.246 -18.806 -19.162 -18.755 -22.423
    Interest Income (Expense), Net Non-Operating -57.82 0.42 0.41 0.288 0.104
    Other, Net -0.008 -0.072 -0.032 0.024 0.005
    Net Income Before Taxes -217.074 -18.458 -18.784 -18.443 -22.314
    Net Income After Taxes -217.081 -18.422 -18.822 -18.234 -22.323
    Net Income Before Extra. Items -217.081 -18.422 -18.822 -18.234 -22.323
    Net Income -217.081 -18.422 -18.822 -18.234 -22.323
    Income Available to Common Excl. Extra. Items -217.081 -18.422 -18.822 -18.234 -22.323
    Income Available to Common Incl. Extra. Items -217.081 -18.422 -18.822 -18.234 -22.323
    Diluted Net Income -217.081 -18.422 -18.822 -18.234 -22.323
    Diluted Weighted Average Shares 3.8226 3.77051 3.81596 3.76792 3.28836
    Diluted EPS Excluding Extraordinary Items -56.7888 -4.88582 -4.93244 -4.83928 -6.78849
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -55.0953 -4.88582 -4.93244 -4.83928 -6.78849
    Revenue 0.688 0.198 0.168 0.174 0.625
    Unusual Expense (Income) 9.959
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 62.258 98.891 149.789 74.505 76.671
    Cash and Short Term Investments 55.711 93.128 146.273 71.949 74.513
    Cash & Equivalents 34.863 15.142 90.095 19.253 22.461
    Short Term Investments 20.848 77.986 56.178 52.696 52.052
    Total Receivables, Net 0.375 0.815 0
    Accounts Receivable - Trade, Net 0
    Prepaid Expenses 6.172 4.948 3.516 2.556 2.158
    Other Current Assets, Total
    Total Assets 71.144 109.926 161.618 83.183 77.739
    Property/Plant/Equipment, Total - Net 7.247 9.153 9.94 7.167 1.018
    Property/Plant/Equipment, Total - Gross 11.391 11.955 11.923 8.222 1.77
    Accumulated Depreciation, Total -4.144 -2.802 -1.983 -1.055 -0.752
    Other Long Term Assets, Total 1.639 1.882 1.889 1.511 0.05
    Total Current Liabilities 14.656 20.144 16.443 18.359 10.239
    Accounts Payable 0.677 3.319 2.254 3.154 0.663
    Accrued Expenses 13.446 14.048 14.162 15.177 9.576
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.517 2.359 0
    Total Liabilities 20.839 25.985 21.786 23.102 10.311
    Total Long Term Debt 0 0.016 0.045 0.031 0
    Other Liabilities, Total 6.183 5.825 5.298 4.712 0.072
    Total Equity 50.305 83.941 139.832 60.081 67.428
    Preferred Stock - Non Redeemable, Net 0 0
    Common Stock 0.006 0.005 0.005 0.003 0.002
    Additional Paid-In Capital 475.971 425.765 415.824 255.142 184.314
    Retained Earnings (Accumulated Deficit) -425.624 -341.809 -276.008 -195.115 -116.861
    Other Equity, Total -0.048 -0.02 0.011 0.051 -0.027
    Total Liabilities & Shareholders’ Equity 71.144 109.926 161.618 83.183 77.739
    Total Common Shares Outstanding 2.61401 1.97421 1.91836 1.16338 0.9656
    Current Port. of LT Debt/Capital Leases 0.016 0.418 0.027 0.028
    Capital Lease Obligations 0 0.016 0.045 0.031
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 205.949 239.886 44.375 62.258 82.219
    Cash and Short Term Investments 203.599 235.358 38.478 55.711 73.676
    Cash & Equivalents 90.592 235.358 35.243 34.863 38.989
    Short Term Investments 113.007 0 3.235 20.848 34.687
    Total Receivables, Net 0.163 1.646 0.33 0.375 0.669
    Accounts Receivable - Trade, Net
    Prepaid Expenses 2.187 2.882 5.567 6.172 7.874
    Total Assets 207.265 243.529 52.453 71.144 91.566
    Property/Plant/Equipment, Total - Net 0 2.316 6.69 7.247 7.069
    Other Long Term Assets, Total 1.316 1.327 1.388 1.639 2.278
    Total Current Liabilities 44.872 232.234 12.637 14.656 17.678
    Accounts Payable 21.501 23.664 2.062 0.677 4.178
    Accrued Expenses 15.861 32.758 10.273 13.446 12.995
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 7.51 175.812 0.302 0.517 0.505
    Total Liabilities 65.562 253.575 18.801 20.839 24.011
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 20.69 21.341 6.164 6.183 6.333
    Total Equity 141.703 -10.046 33.652 50.305 67.555
    Common Stock 0.007 0.006 0.006 0.006 0.006
    Additional Paid-In Capital 455.957 453.741 477.698 475.971 474.535
    Retained Earnings (Accumulated Deficit) -701.234 -661.127 -444.046 -425.624 -406.802
    Other Equity, Total -0.132 0.011 -0.006 -0.048 -0.184
    Total Liabilities & Shareholders’ Equity 207.265 243.529 52.453 71.144 91.566
    Total Common Shares Outstanding 4.04869 3.24007 2.61581 2.61401 2.46044
    Current Port. of LT Debt/Capital Leases 0.016
    Capital Lease Obligations 0
    Property/Plant/Equipment, Total - Gross 11.391
    Accumulated Depreciation, Total -4.144
    Preferred Stock - Non Redeemable, Net 387.105 197.323
    Total Preferred Shares Outstanding 1.08634 0.72145
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -83.815 -65.801 -80.893 -78.254 -44.348
    Cash From Operating Activities -80.144 -53.716 -75.775 -65.692 -32.193
    Cash From Operating Activities 1.567 1.576 0.996 0.418 0.293
    Non-Cash Items 7.607 8.676 6.662 5.04 4.661
    Changes in Working Capital -5.503 1.833 -2.54 7.104 7.201
    Cash From Investing Activities 57.008 -22.619 -7.604 -1.739 -15.231
    Capital Expenditures -0.038 -0.573 -4.28 -1.492 -0.422
    Other Investing Cash Flow Items, Total 57.046 -22.046 -3.324 -0.247 -14.809
    Cash From Financing Activities 42.678 1.393 154.512 65.723 57.068
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net 43.096 1.903 154.532 65.748 57.068
    Net Change in Cash 19.436 -74.957 71.184 -1.708 9.644
    Issuance (Retirement) of Debt, Net -0.418 -0.51 -0.02 -0.025
    Foreign Exchange Effects -0.106 -0.015 0.051
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -18.422 -83.815 -64.993 -46.759 -24.436
    Cash From Operating Activities -17.634 -80.144 -62.004 -46.936 -26.263
    Cash From Operating Activities 0.384 1.567 1.182 0.781 0.403
    Non-Cash Items 1.768 7.607 6.152 4.518 2.179
    Changes in Working Capital -1.364 -5.503 -4.345 -5.476 -4.409
    Cash From Investing Activities 17.75 57.008 43.008 26.509 25.759
    Capital Expenditures 0 -0.038 -0.038 -0.037 -0.037
    Other Investing Cash Flow Items, Total 17.75 57.046 43.046 26.546 25.796
    Cash From Financing Activities 0.01 42.678 42.686 42.816 0.012
    Issuance (Retirement) of Stock, Net 0.018 43.096 43.096 43.163 0.184
    Issuance (Retirement) of Debt, Net -0.008 -0.418 -0.41 -0.347 -0.172
    Foreign Exchange Effects 0.011 -0.106 -0.152 -0.095 -0.023
    Net Change in Cash 0.137 19.436 23.538 22.294 -0.515

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Aeglea Bio Therapeutics Company profile

    About Aeglea Bio Therapeutics Inc

    Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Aeglea Bio Therapeutics Inc revenues increased from $0K to $18.7M. Net loss decreased 19% to $65.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.33.

    Industry: Bio Therapeutic Drugs

    221 Crescent Street
    Suite 105
    WALTHAM
    MASSACHUSETTS 02453
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    XRP/USD

    0.51 Price
    +0.530% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    ETH/USD

    3,047.81 Price
    -0.760% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    63,595.75 Price
    +0.140% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    US100

    17,037.80 Price
    -1.980% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading